US FDA grants standard approval of EisaiBiogen Alzheimer's drug Leqembi, widening access to the therapy
Marking a new milestone for a fatal disease that's eluded drugmakers' efforts for decades
Stay updated with breaking news from Ivan Cheung. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Marking a new milestone for a fatal disease that's eluded drugmakers' efforts for decades
The FDA approved Leqembi for people with early Alzheimer's disease on Thursday, making it easier for older adults to obtain the first drug to slow memory and thinking issues.
(CNN) — The US Food and Drug Administration on Thursday granted traditional full approval to the Alzheimer’s drug Leqembi, the first medicine proven to slow the course<a class="excerpt-read-more" href="https://wsvn.com/news/us-world/first-alzheimers-drug-to-slow-disease-progression-gets-full-fda-approval-likely-triggering-broader-medicare-coverage/">Read More</a>
Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review.
Leqembi is the first Alzheimer’s antibody treatment to receive full FDA approval.